DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,803,545 | -30.1% | 378,262 | -0.0% | 0.74% | -13.8% |
| Q2 2023 | $11,162,659 | +66.9% | 378,267 | +30.3% | 0.86% | +51.9% |
| Q1 2023 | $6,689,203 | +92203.1% | 290,330 | +11.4% | 0.57% | -13.0% |
| Q4 2022 | $7,247 | -99.9% | 260,604 | 0.0% | 0.65% | -18.4% |
| Q3 2022 | $7,998,000 | +853.3% | 260,604 | +813.8% | 0.80% | +852.4% |
| Q2 2022 | $839,000 | -28.8% | 28,519 | +7.8% | 0.08% | -9.7% |
| Q1 2022 | $1,179,000 | 0.0% | 26,445 | 0.0% | 0.09% | 0.0% |
| Q4 2021 | $1,179,000 | +84.2% | 26,445 | +108.3% | 0.09% | +63.2% |
| Q3 2021 | $640,000 | +97.5% | 12,695 | +207.2% | 0.06% | +96.6% |
| Q2 2021 | $324,000 | – | 4,133 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |